Evidence map›Paper›PMID 40536285›Full record

Trial reportCPT: pharmacometrics & systems pharmacology2025

Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV

Li Zhang, John D Davis, Vanaja Kanamaluru, Christine Xu

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Li ZhangSanofi, Bridgewater, New Jersey, USA.
John D DavisRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Vanaja KanamaluruSanofi, Bridgewater, New Jersey, USA.
Christine XuSanofi, Bridgewater, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigated the pharmacokinetic/pharmacodynamic (PK/PD) relationship of dupilumab as an add-on therapy in the intent-to-treat (ITT) uncontrolled moderate-to-severe asthma population and identified the factors significantly contributing to variability in forced expiratory volume in 1 second; (FEV

Indexed as

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaModels, BiologicalAdolescentAdultAgedDose-Response Relationship, DrugDouble-Blind MethodFemaleForced Expiratory VolumeHumansMaleMiddle AgedSeverity of Illness IndexYoung AdultAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanizeddupilumabasthmadupilumabforced expiratory volume in 1 smonoclonal antibodiespopulation pharmacokinetic/pharmacodynamic

Identifiers

PMID40536285
PMCPMC12358309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.